Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone Quadrivalent in Children 6 to 35 Months of Age
Phase of Trial: Phase III
Latest Information Update: 29 Nov 2017
Price : $35 *
At a glance
- Drugs GSK 2282512A (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 21 Nov 2016 According to a GSK media release, based on the data from this and other three studies, the US FDA approved supplemental Biologics License Application for FluLaval Quadrivalent (Influenza Vaccine) for use in children of 6 months and older.
- 11 Apr 2016 Treatment arms changed from 4 to 2.